Revvity provides products, services and solutions for the diagnostics, life sciences and applied markets. Co. ‘s segments are: Discovery and Analytical Solutions and Diagnostics. Co.'s Discovery and Analytical Solutions segment serves: the life sciences, which consist of the life sciences research market and laboratory services market; and applied markets, which consist of environmental, food and industrial markets. Co.'s Diagnostics segment provides instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians and medical research personnel. Co.'s Diagnostics segment is focused on reproductive health, immunodiagnostics, diagnostics and applied genomics.
When researching a stock like Revvity, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from RVTY Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for RVTY stock — the real life supply and demand for the stock over time — and examines that data in different ways. One of these ways is called the Relative Strength Index, or RSI. This popular indicator, originally developed in the 1970's by J. Welles Wilder, looks at a 14-day moving average of a stock's gains on its up days, versus its losses on its down days. The resulting RVTY RSI is a value that measures momentum, oscillating between "oversold" and "overbought" on a scale of zero to 100. A reading below 30 is viewed to be oversold, which a bullish investor could look to as a sign that the selling is in the process of exhausting itself, and look for entry point opportunities. A reading above 70 is viewed to be overbought, which could indicate that a rally in progress is starting to get crowded with buyers. If the rally has been a long one, that could be a sign that a pullback is overdue. |